From patients and care providers to pharmaceutical companies and public procurers, sustainable, innovative healthcare is clearly a goal for all. At the same time, only 34% believe they will have access to the best cancer medicines if treated in Norwegian public hospitals, according to Kantar TNS.
R&D investment vs. cost containment is at the core of many of today’s healthcare debates – in Norway and abroad. How can we best address this ongoing struggle?
Please join members of parliament, healthcare providers, international company directors and, most importantly, patients (potentially all of us!) as we delve deeper than the tabloid headlines that often frame dialogue on sustainable, innovative healthcare.